AKBAAkebia Therapeutics, Inc.

$365M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$295M-12.0% YoY

Gross Profit

$231M78.3% margin

Operating Income

-$378M-128.2% margin

Net Income

-$385M-130.6% margin

EPS (Diluted)

$-2.53

Cash Flow

Operating Cash Flow

-$110M

Free Cash Flow

-$111M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$644M

Total Liabilities

$397M

Stockholders' Equity

$248M

Cash & Equivalents

$229M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$295M	$335M	-12.0%
Gross Profit	$231M	$190M	+21.6%
Operating Income	-$378M	-$286M	-32.0%
Net Income	-$385M	-$280M	-37.6%

AKBA FY 2020 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena